These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34536265)

  • 21. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure.
    Kubota Y; Tay WT; Asai K; Murai K; Nakajima I; Hagiwara N; Ikeda T; Kurita T; Teng TK; Anand I; Lam CSP; Shimizu W;
    ESC Heart Fail; 2018 Apr; 5(2):297-305. PubMed ID: 29055972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Ferreira JP; Butler J; Zannad F; Filippatos G; Schueler E; Steubl D; Zeller C; Januzzi JL; Pocock S; Packer M; Anker SD
    J Am Coll Cardiol; 2022 Mar; 79(12):1129-1137. PubMed ID: 35331406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure.
    Vaduganathan M; Ferreira JP; Rossignol P; Neuen BL; Claggett BL; Pfeffer MA; McMurray JJV; Pitt B; Zannad F; Solomon SD
    Eur J Heart Fail; 2022 Sep; 24(9):1586-1590. PubMed ID: 35867859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
    Rossignol P; Duarte K; Girerd N; Karoui M; McMurray JJV; Swedberg K; van Veldhuisen DJ; Pocock S; Dickstein K; Zannad F; Pitt B
    Eur J Heart Fail; 2020 Aug; 22(8):1402-1411. PubMed ID: 31919958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure.
    Lin DS; Lin FJ; Lin YS; Lee JK; Lin YH
    Eur J Heart Fail; 2023 Jan; 25(1):98-107. PubMed ID: 36404402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction.
    Lin CH; Yeh JK; Lin TY; Lo YL; Chang BJ; Ju JS; Chiu TH; Tung PH; Huang YJ; Lin SM
    BMC Pulm Med; 2023 Feb; 23(1):67. PubMed ID: 36805703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Canepa M; Straburzynska-Migaj E; Drozdz J; Fernandez-Vivancos C; Pinilla JMG; Nyolczas N; Temporelli PL; Mebazaa A; Lainscak M; Laroche C; Maggioni AP; Piepoli MF; Coats AJS; Ferrari R; Tavazzi L;
    Eur J Heart Fail; 2018 Jan; 20(1):100-110. PubMed ID: 28949063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis.
    Japp D; Shah A; Fisken S; Denvir M; Shenkin S; Japp A
    Age Ageing; 2017 Jan; 46(1):18-25. PubMed ID: 28181634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease.
    Khan MS; Khan MS; Moustafa A; Anderson AS; Mehta R; Khan SS
    Am J Cardiol; 2020 Feb; 125(4):643-650. PubMed ID: 31843235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.